Samedan Ltd Pharmaceutical Publishers

Advanced search

Publications

European Pharmaceutical
Contractor

European Biopharmaceutical
Review

International Clinical Trials

Pharmaceutical Manufacturing
and Packing Sourcer

Innovations in Pharmaceutical
Technology

Subscribe Online

Conferences

White Papers

Samedan app

Pharmaceutical Directory

Industry Events Calendar

News and Press Releases

Employment Opportunities

Advertising with us

Air Transport Publications

home > ebr > Winter 2013

PUBLICATIONS

European Biopharmaceutical Review

Winter 2013

Text

PDF

BioResearch and Innovation

Cell Based Therapies

Nobels and Stem Cells

The work of Sir John Gurdon and Shinya Yamanaka was recently awarded the Nobel Prize in Physiology or Medicine. Their groundbreaking work has led Dean Griffiths at Cambridge Consultants to investigate how a major discovery can start from a minor question.

Single-use Bioreactors

Rapid Reaction

Traditional stainless steel reactors are being overtaken by single-use bioreactors. Lee Madrid at EMD Millipore Corporation and Aurore Poles-Lahille at Millipore SAS outline the advantages that this new technology can bring.

Discovery Technology

Cloud Computing

Up, Up and Away

Inefficient data processing often stifles innovation in research and development. Richard Heitmann at Aspera discusses the vast possibilities to be gained in new medical advancements when modern technology is used to its full potential.

BioDevelopment

Sharing Data

Personal Medicine

In order to provide more bespoke therapeutics for cancer treatment, the industry needs to make a more conscious effort to collaborate and share patient data, says Markus Warmuth at H3 Biomedicine.

Drug Discovery

Stem Cell Technology

Treatment from Within

Distinguishing the correct cell types in liver cell transplantation is a vital factor that contributes substantially to the success of this therapy. Eric Halioua and Etienne Marc Sokal atPromethera Biosciences explore the advantages that intrahepatic cells have over other sources.

Differentiated Cells

iPS Power

The world of patient therapeutics can be drastically transformed through the use of in vitro differentiated cells that are derived from human induced pluripotent stem cells, Felix Haniel of Axiogenesis AG explains.

Safety Profile

A Marked Difference

Biomarkers are an invaluable tool in drug discovery and development. Federica Crivellente and Elena Vicentini at Aptuit suggest that the use of high throughput technologies can help to generate high quality data in a more efficient and cost-effective way.

Stem Cells in Drug Discovery

Patient in a Dish

Roberto Iacone at Roche and Blake Anson at Celluar Dynamics International examine how using improved induced pluripotent stem cell models will result in more effective medicines and help to overcome some of the challenges in this field.

BioRegional

Biosimilars: Asian Markets

Biotech in China

James C Greenwoodat Biotechnology Industry Organization assesses the growth of the Chinese biotech industry and how investment into new products could secure their position in the drug development and manufacturing market.

DEVELOPMENT AND PRODUCTION

Cell Line Development

Database Power

When trying to identify new cell lines, progress can be stifled by the data management process. If a more highly developed system were to be implemented, development timelines would decrease rapidly, as Eliot Randle at IDBS demonstrates.

Diabetes Therapeutics

Crackling the Code

A promising alternative for the treatment of type 1 diabetes has been discovered. Peter Hosking at Living Cell Technologies illustrates how using encapsulated porcine insulin-producing cells significantly reduces the number of hypoglycaemic events.

Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd

Published quarterly in
January, April,
July and October

News and Press Releases

Saneca Pharma strengthens senior team

Slovakia-based CDMO adds senior talent to its team to position the company for continued growth
More info >>

All releases >>

White Papers

High Potency Drugs – from Molecule to Market

PCI Pharma Services

PCI Pharma Services has invested in state-of-the-art containment equipment and created a ‘Potent Passport’ philosophy to identify the specific handling requirements for any Highly Potent Active Pharmaceutical Ingredients (HPAPI) project. Backed by 30 years’ experience of managing potent molecules, PCI Pharma Services is the logical choice when selecting an outsourcing partner.
More info >>

All white papers >>

Industry Events

Outsourcing in Clinical Trials Medical Devices 2017

27-28 June 2017, Santa Clara, CA

OCT Medical Devices moved to Irvine, California for the first year in 2016, and we are pleased to say it proved a resounding success. As the only event to cater for the Southern California Medical device hub in Irvine, it brought together a variety of medical device companies of all sizes, including Medtronic, Edwards Lifesciences, Onciomed, Inc and St Jude Medical.
More info >>

All events >>